Published by Josh White on 12th July 2018
(Sharecast News) - Fund management and strategic investor group Braveheart Investment Group noted on Thursday that Paraytec has engaged an adviser to raise £4m of equity fundraising, in order to fund the further development, regulatory approval and commercialisation of its urine test for the detection and monitoring of bladder cancer.